Floatz logo

mk-3475

Recurrent Lung Carcinoma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universitymonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

68 Active assets in the Recurrent Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Carboplatin
SystImmune Inc.
Phase 3B

View all 50 →

Same molecule, other indications

mk-3475 is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
60 / 100
View asset →
MSI Positive Non-Colorectal CancersDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →